SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-22-309236
Filing Date
2022-12-21
Accepted
2022-12-20 17:41:00
Documents
1
Group Members
INVOPPS GP IV, L.L.C.INVOPPS IV, L.P.SACHA LAINOVIC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d407630dsc13da.htm SC 13D/A 79752
  Complete submission text file 0001193125-22-309236.txt   81374
Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Subject) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91186 | Film No.: 221475972
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 126 EAST 56TH STREET, 20TH FLOOR NEW YORK NY 10022
Business Address 126 EAST 56TH STREET, 20TH FLOOR NEW YORK NY 10022 212-616-2555
InvOpps IV US, L.P. (Filed by) CIK: 0001745076 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A